Acta Medica Okayama volume74 issue5
2020-10 発行

Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab

Hirabae, Atsuko Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ichihara, Eiki Department of Allergy and Respiratory Medicine, Okayama University Hospital Kaken ID publons
Sunami, Ryota Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ota, Moeko Department of Allergy and Respiratory Medicine, Okayama University Hospital
Iwamoto, Yoshitaka Department of Allergy and Respiratory Medicine, Okayama University Hospital
Maeda, Yoshinobu Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID researchmap
Kiura, Katsuyuki Department of Allergy and Respiratory Medicine, Okayama University Hospital ORCID Kaken ID publons researchmap
Publication Date
2020-10
Abstract
We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.
Document Type
Case Report
Keywords
lung cancer
immune checkpoint inhibitors
pembrolizumab
hyperprogression
Link to PubMed
74_5_423.pdf 2.94 MB